Skip to main content

Grossman Jerrold B's Form 4 filing

Adma Biologics, Inc. (ADMA) · filed Aug 30, 2024

Accession no.
0001140361-24-039821
Filed
Aug 30, 2024
Trade date
Aug 29, 2024
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $2.36M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Grossman Jerrold BCIK 0001542519Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 29, 2024Common StockMOption exerciseAcquired+118,861$3.66+$435,031.26586,166Direct
Aug 29, 2024Common StockMOption exerciseAcquired+9,000$5.96+$53,640595,166Direct
Aug 29, 2024Common StockMOption exerciseAcquired+9,000$10.80+$97,200604,166Direct
Aug 29, 2024Common StockSSaleDisposed−136,861$17.27F1−$2,363,589.47467,305Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 29, 2024Common StockMOption exerciseDisposed−118,861$3.66−$435,031.260Direct
Aug 29, 2024Common StockMOption exerciseDisposed−9,000$5.96−$53,6400Direct
Aug 29, 2024Common StockMOption exerciseDisposed−9,000$10.80−$97,2000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.595. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit 24 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)